Novo Nordisk
-
Novo Nordisk oral semaglutide shows superior glycemic control in teens
The study showed that oral semaglutide achieved a significantly greater reduction in HbA1c levels, a key marker of blood sugar control, compared to placebo.
-
OpenAI collaborates with Novo Nordisk to accelerate drug discovery through advanced AI technology
The collaboration will enhance the company’s ability to analyze complex datasets, identify promising drug candidates, and significantly reduce the time required to bring medications to patients.
-
ADPHC taps Novo Nordisk expertise to launch precision weight management program in Abu Dhabi
A central focus of the partnership is equipping family physicians and other healthcare professionals to better identify and support individuals at risk.
-
Novo Nordisk’s Awiqli receives FDA approval for type 2 diabetes patients
Awiqli® changes that by offering a single weekly dose, giving patients greater flexibility to fit treatment into their individual lifestyles and preferences.
-
Novo Nordisk secures FDA approval for high-dose wegovy as patent expiry looms
Wegovy HD became the fourth drug to receive FDA approval through the Commissioner’s National Priority Voucher pilot programme.
-
Indian pharma giants launch generic Semaglutide as Novo Nordisk patent expires
The companies are competing for a share of India’s Semaglutide market, which analysts estimate will reach USD1 billion over the next two years.
-
Novo Nordisk invests USD470M to expand GLP-1 tablet production in Ireland
The tabletting facility in Athlone represents a cornerstone of Novo Nordisk’s long-term strategy to strengthen its presence in Ireland and enhance its global manufacturing footprint.
-
Novo Nordisk collaborates with Vivtex to develop oral biologic medicines for obesity
The agreement grants Novo Nordisk licensing rights to select oral drug-delivery technologies from Vivtex.